| Antimicrobial Agent Abbreviations | |||||||||||||||||
| Amp- Ampicilin, Amox/Clav- Amoxicillin/Clavulanate, Amp/Sulb-Ampicillin/Sulbactam, Amik- Amikacin, Aztre-Aztreonam, Cefaz- Cefazolin, Ceftaz-Ceftazidime, Cefep-Cefepime, Chloro-Chloramphenicol, Clinda-Clindamycin, Eryth-Erythromycin, Gent-Gentamicin, Imip-Imipenem, Levo-Levofloxacin,Linz-Linezolid, Mero-Meropenem, Nitro-Nitrofurantoin, Norflox- Norfloxacin, Naf-Nafcillin, Pen-Penicillin, Pip/Tazo-Pipercillin/Tazobactam, Quin-Dalf-Quinupristin-Dalfopristin, Tetra-Tetracycline, Tmp/Sxt- Trimethoprim/Sulfamethoxazole, Tobra-Tobramycin, Vanco-Vancomycin | |||||||||||||||||
| HUP Inpatients, Jan-June 2011, Blood Isolates | |||||||||||||||||
| Percent Susceptible | |||||||||||||||||
| Organism | No | Amp or Pen | Amp/Sulb or Amox/Clav | Cefaz | Clinda | Eryth | Gent | Naf | Tmp/Sxt | Levo | Tetra | Linz | Quin-Dalf | Vanco | |||
| S. aureus | 100 | 0 | 63 | 63 | 71 | 51 | 96 | 63 | 96 | 65 | nt | 100 | 100 | 100 | |||
| Coagulase negative Staphylococcus spp. | 84 | 0 | 19 | 19 | 49 | 33 | 58 | 19 | nt | 23 | nt | 100 | 100 | 100 | |||
| Enterococcus sp | 92 | 40 | nt | R | nt | nt | 91(96)hl* | nt | R | 35 | 12 | 100 | nt | 50 | |||
| *hl- high level gentamicin, 500 ug/ml, high level streptomycin, 2000 ug/ml, in parenthesis | nt-not tested | R-intrinsic resistance | |||||||||||||||
| Percent Susceptible | |||||||||||||||||
| Organism | No. | Amp | Amp/Sulb or Amox/Clav | Cefaz | Ceftaz | Cefep | Gent | Tobra | Amik | Levo | Pip | Pip/Tazo | Tmp/Sxt | Mero | |||
| E. coli | 73 | 47 | 81 | 67 | 96 | 97 | 90 | 90 | 100 | 77 | 48 | 96 | 74 | 100 | |||
| E. cloacae | 13 | 0 | 0 | 0 | 77 | 77 | 92 | 85 | 100 | 85 | 62 | 62 | 69 | 100 | |||
| K. oxytoca | 10 | 0 | 80 | 0 | 80 | 90 | 100 | 90 | 100 | 100 | 0 | 70 | 90 | 90 | |||
| K. pneumoniae | 53 | 0 | 90 | 65 | 85 | 91 | 87 | 87 | 91 | 89 | 0 | 84 | 75 | 94 | |||
| P. aeruginosa | 35 | R | R | R | 94 | 94 | 63 | 97 | 100 | 80 | 94 | 94 | R | 91 | |||
| S. marcescens | 7 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 71 | 72 | 86 | 86 | 100 | |||
| R-intrinsic resistance | |||||||||||||||||
| HUP Inpatients, Jan-June 2011, Non-Urinary Isolates | |||||||||||||||||
| Percent Susceptible | |||||||||||||||||
| Organism | No | Amp or Pen | Amp/Sulb or Amox/Clav | Cefaz | Clinda | Ery | Gent | Naf | Tmp/Sxt | Levo | Tetra | Linz | Quin-Dalf | Vanco | |||
| S. aureus | 443 | 0 | 49 | 49 | 56 | 33 | 98 | 49 | 98 | 53 | nt | 100 | 100 | 100 | |||
| Coagulase negative Staphylococcus spp. | 45 | 0 | 44 | 44 | 60 | 44 | 80 | 44 | nt | 51 | nt | 100 | 100 | 100 | |||
| Enterococcus sp | 147 | 55 | nt | R | nt | nt | nt | nt | R | 44 | 21 | 100 | nt | 64 | |||
| nt-not tested | R-intrinsic resistance | ||||||||||||||||
| Organism | No. | Amp | Amp/Sulb or Amox/Clav | Cefaz | Ceftaz | Cefep | Gent | Tobra | Amik | Levo | Mero | Pip | Pip/Tazo | Tmp/Sxt | |||
| A. baumanii | 33 | 0 | 100 | 0 | 29 | 29 | 37 | 41 | 36 | 27 | 31 | 22 | 22 | 34 | |||
| C. koseri | 24 | 0 | 96 | 90 | 96 | 100 | 100 | 100 | 100 | 96 | 100 | 0 | 67 | 100 | |||
| Pantoea (Enterobacter) aerogenes | 39 | 0 | 0 | 0 | 82 | 97 | 97 | 100 | 100 | 100 | 100 | 79 | 87 | 95 | |||
| E. cloacae | 61 | 0 | 0 | 0 | 61 | 87 | 85 | 77 | 98 | 87 | 93 | 59 | 67 | 82 | |||
| E. coli | 178 | 47 | 69 | 56 | 91 | 92 | 87 | 81 | 100 | 87 | 99 | 49 | 86 | 71 | |||
| K. pneumoniae | 149 | 0 | 67 | 45 | 66 | 70 | 76 | 70 | 92 | 70 | 77 | 0 | 68 | 65 | |||
| K. oxytoca | 24 | 0 | 67 | 26 | 92 | 92 | 100 | 100 | 100 | 92 | 100 | 0 | 54 | 92 | |||
| M. morganii | 12 | 0 | 0 | 0 | 92 | 100 | 100 | 100 | 100 | 83 | 100 | 75 | 88 | 83 | |||
| P. mirabilis | 61 | 92 | 98 | 86 | 100 | 98 | 97 | 97 | 100 | 92 | 100 | 95 | 100 | 92 | |||
| P. aeruginosa | 353 | R | R | R | 77 | 81 | 62 | 91 | 91 | 68 | 69 | 72 | 72 | R | |||
| S. marcescens | 58 | 0 | 0 | 0 | 93 | 95 | 98 | 97 | 100 | 95 | 97 | 84 | 84 | 93 | |||
| HUP Inpatients, Jan-June 2011, Urinary Isolates | |||||||||||||||||
| Percent Susceptible | |||||||||||||||||
| Organism | No | Amp or Pen | Amp/Sulb or Amox/Clav | Cefaz | Ery | Clinda | Gent | Naf | Nitro | Tmp/Sxt | Levo | Tetra | Linz | Quin-Dalf | Vanco | ||
| S. aureus | 22 | 0 | 55 | 55 | 32 | 45 | 100 | 55 | 100 | 95 | 45 | nt | 100 | 100 | 100 | ||
| Coagulase negative Staphlococcus spp. | 89 | 0 | 35 | 35 | 37 | 51 | 73 | 35 | 98 | nt | 26 | nt | 100 | 100 | 100 | ||
| Enterococcus sp | 304 | 49 | nt | nt | nt | nt | nt | nt | 49 | nt | 41 | 15 | 100 | na | 54 | ||
| *hl- high level gentamicin, 500 ug/ml, high level streptomycin, 2000 ug/ml, in parenthesis | na-not available | ||||||||||||||||
| **CNS not routinely tested for inducible clindamycin resistance, susceptibility may be higher | |||||||||||||||||
| Percent Susceptible | |||||||||||||||||
| Organism | No. | Amp | Amp/Sulb or Amox/Clav | Cefaz | Ceftaz | Cefp | Gent | Tobra | Amik | Levo | Mero | Nitro | Norflox | Pip | Pip/Tazo | Tmp/Sxt | Tetra |
| A. baumanii | 9 | 0 | 100(0) | 0 | 30 | 30 | 40 | nt | 44 | 30 | 30 | nt | 30 | 20 | 30 | 70 | 40 |
| Pantoea (Enterobacter) aerogenes | 11 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 9 | 100 | 100 | 100 | 100 | 100 |
| E. cloacae | 25 | 0 | 0 | 0 | 48 | 76 | 92 | 80 | 100 | 68 | 88 | 16 | 68 | 36 | 48 | 48 | 69 |
| E. coli | 447 | 44 | 74 | 84 | 91 | 93 | 88 | 89 | 100 | 68 | 100 | 93 | 68 | 46 | 100 | 70 | 71 |
| K. pneumoniae | 168 | 0 | 73 | 68 | 70 | 77 | 77 | 80 | 90 | 72 | 80 | 25 | 73 | 0 | 89 | 64 | 78 |
| K. oxytoca | 26 | 0 | 77 | 38 | 88 | 96 | 98 | 100 | 100 | 92 | 100 | 73 | 96 | 0 | 69 | 96 | 92 |
| P. mirabilis | 54 | 92 | 100 | 92 | 100 | 98 | 93 | 96 | 100 | 85 | 100 | 0 | 85 | 92 | 100 | 81 | 0 |
| P. aeruginosa | 101 | nt | R | R | 88 | 87 | 55 | 93 | 90 | 71 | 84 | R | nt | 87 | 83 | R | nt |
| S. marscesens | 10 | 0 | 0 | 0 | 80 | 80 | 100 | 100 | 100 | 80 | 80 | 0 | 70 | 80 | 80 | 90 | 0 |